If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - Series 5. Ep.30
August 28, 2026 - - Podcast -
Sandoz earns workplace recognition amid push for medicine access
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Patients Australia puts healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Weight loss medicines drive revenue growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News
